Clinical Trial

NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX System

Study acronym: NANOPULSE-AF
Recruiting
View on ClinicalTrials.gov →
Summary
The objective of this study is to demonstrate the safety and effectiveness of the CellFX nano-second Pulsed Field Ablation (nsPFA) Cardiac Catheter Ablation System in treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation (AF).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-05; most recent amendment 2026-05-03.
Status change: Not Yet Recruiting → Recruiting 2026-05-03
Trial Details
NCT Number NCT07018596
Lead Sponsor Pulse Biosciences, Inc.
Conditions Atrial Fibrillation Paroxysmal, Cardiac Ablation, Cardiac Arrhythmia
Enrollment 215 participants
Start Date 2026-04-06
Primary Completion 2026-10 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-06